GNNSF News and Press, Genscript Biotech Corp From 11/15/20

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion...

Maravai LifeSciences has filed to raise $1.275 billion in an IPO. The firm provides a range of products and services to biopharmaceutical research organizations worldwide. MRVI is generating strong growth results across all major metrics, has a solid balance sheet and excellent gr...

The FDA authorizes the emergency use of Genscript Biotech's ([[GNNSF]]) cPass SARS-CoV-2 Neutralizing Antibody Detection Kit for the identification of neutralizing antibodies to the coronavirus from recent or prior infection.This is the first assay approved in the U.S. that detects SARS-CoV-2...

Maravai LifeSciences has filed for a U.S. IPO. The firm sells gene, cell and RNA products and services to biopharma firms and academic institutions worldwide. MRVI has shown impressive revenue growth and operates in an industry expected to grow at a substantial rate in the coming ...

Graphic Source: Twist Bioscience Corporation Introduction: What is Twist Biosciences? Twist Bioscience Corporation (TWST) is a high-growth synthetic biology company that launched a uniquely low-cost DNA synthesis platform in 2016 based on proprietary silicon chip DNA writing. This has si...

In early January, researchers identified an irregular, lethal pneumonia spreading through China as the disease we now know as COVID-19. Global efforts to identify, treat, and limit the spread of the disease mobilized unprecedented resources toward Genomics, a cutting-edge field of biology with...

Genscript ( OTC:GNNSF ) has agreed to collaborate with Duke-NUS Medical School and the Diagnostics Development Hub at Singapore's Agency for Science, Technology and Research (ASTAR) to co-develop and manufacture a novel blood test for COVID-19 neutralizing antibodies called a surrogate vir...

Deals and Financings Ping An (PNGAY), a China insurance company, announced a $311 million agreement with Japan's Shionogi to develop new drugs for infectious diseases and CNS needs based on Ping An's lifestyle data. For its $311 million, Ping An will receive a 2% stake in Shionogi shares. Th...

Genscript Biotech Corporation ( OTC:GNNSF ): FY Gross profit of $180.3M. More news on: Genscript Biotech Corporation, Earnings news and commentary, Read more ...

Deals and Financings Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson &am...